
GSK Plans A $2.5 Billion Restructure to Expedite the Development of New Medications
GSK Plans A $2.5 Billion Restructure to Expedite the Development of New Medications As CEO Luke Miels strives to fulfill his pledge of accelerated drug development, GSK (GSK.L) opened a new tab on Tuesday, launching a £1.9 billion ($2.52 billion) cost-savings drive to help support the British drugmaker’s increased late-stage study roster. In order to ensure investors that GSK can





















